tiprankstipranks
Trending News
More News >
VivoPower (VIVO)
NASDAQ:VIVO

VivoPower (VIVO) Price & Analysis

Compare
649 Followers

VIVO Stock Chart & Stats

$2.86
-$0.14(-8.18%)
At close: 4:00 PM EST
$2.86
-$0.14(-8.18%)

Bulls Say, Bears Say

Bulls Say
Strategic Pivot To AI Data-center InfrastructureThe company’s formal shift to aggregating power‑secured land and leasing long‑term, bankable data‑center sites aligns it with structural AI compute demand. Focusing on asset ownership and leases yields recurring, contractually-backed cash flows and lowers technology operating risk versus running compute tenants.
Secured $30M PIPE With Strategic InvestorsThe $30M PIPE provides near‑term, non‑operational capital targeted at scaling the AI data center portfolio. Participation by specialist and sovereign investors adds credibility, potential strategic relationships, and funding runway to advance asset acquisition and lease structuring without immediate dilution from public ATM issuance.
Ownership/access To Powered Sites In Strategic MarketsControlling powered sites in multiple jurisdictions secures a scarce input—power‑secured land—creating a durable competitive advantage. Ownership or exclusive access reduces site development risk, accelerates leasing to sovereigns and hyperscalers, and builds a tangible asset base that can generate long‑term lease revenue.
Bears Say
Persistent Negative Margins And Revenue VolatilitySustained negative gross and net margins and volatile revenue signal that the core business has not yet achieved profitable scale. This undermines internal funding capacity, increases dependence on external capital for project buildout, and lengthens the time horizon to consistent, sustainable profitability.
High Leverage And Intermittent Negative EquityElevated leverage and episodes of negative equity constrain financial flexibility, heighten refinancing risk, and can limit the company’s ability to bid for or finance large infrastructure projects. In capital‑intensive data center builds, this raises the cost of capital and execution risk over the medium term.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate the business currently cannot self‑fund growth or absorb setbacks. Continued reliance on external financing increases vulnerability to market disruptions and may force dilutive or expensive funding choices when scaling capital‑intensive data‑center assets.

VIVO FAQ

What was VivoPower’s price range in the past 12 months?
VivoPower lowest stock price was $0.74 and its highest was $8.88 in the past 12 months.
    What is VivoPower’s market cap?
    VivoPower’s market cap is $39.79M.
      When is VivoPower’s upcoming earnings report date?
      VivoPower’s upcoming earnings report date is Aug 31, 2026 which is in 164 days.
        How were VivoPower’s earnings last quarter?
        Currently, no data Available
        Is VivoPower overvalued?
        According to Wall Street analysts VivoPower’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does VivoPower pay dividends?
          VivoPower does not currently pay dividends.
          What is VivoPower’s EPS estimate?
          VivoPower’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does VivoPower have?
          VivoPower has 16,790,245 shares outstanding.
            What happened to VivoPower’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of VivoPower?
            Currently, no hedge funds are holding shares in VIVO
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Company Description

              VivoPower

              Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
              Similar Stocks
              Company
              Price & Change
              Follow
              Beam Global
              Spruce Power Holding
              Maxeon Solar Technologies
              Turbo Energy, S.A. Sponsored ADR
              SolarMax Technology, Inc.

              Ownership Overview

              <0.01%0.13%99.86%
              Insiders
              0.13% Other Institutional Investors
              99.86% Public Companies and
              Individual Investors
              Popular Stocks